Novel treatment of bronchial asthma: Application of leukotriene receptor antagonists and biosynthesis inhibitors;Nieuwe therapie van asthma bronchiale: Toepassing van leukotrieenreceptorantagonisten en leukotrieensyntheseremmers

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 2, 1998, Pages 72-78

  Diamant, Z ^a   Sterk, P J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CORTICOSTEROID THERAPY; DISEASE SEVERITY; HUMAN; REVIEW; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; PRACTICE GUIDELINES;

EID: 0032501720     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Djukanovic R, Roche WR, Wilson JW, Beasley CRW, Twentyman OP, Howarth RH, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990,142:434-57.
2. Ebma M, Takahashi T, Chiba T, Motomiya M. Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma A 3-D morphometric study. Am Rev Respir Dis 1993;148:720-6.
3. Global initiative for asthma. Bethesda, Md , USA: National Institutes of Health, National Heart, Lung, and Blood Institute. 1995.
4. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636-42.
5. Sterk PJ, Fabbri LM, Quanjer PH. Cockcroft DW, O'Byrne PM, Anderson SD, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J 1993;16:53-83.
6. Bentley AM, Kay AB, Durham SR. Human late asthmatic reactions. Clin Exp Allergy 1997;27 Suppl 1:71-86.
7. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323.645-55.
8. Holtzman MJ. Arachidonic acid metabolism Implications of biological chemistry for lung function and disease. Am Rev Respir Dis 1991;143:188-203.
9. Drazen JM, Evans JF, Stevens RL, Shipp MA. Inflammatory effector mechanisms in asthma. Am J Respir Crit Care Med 1995; 152:403-7.
10. Diamant Z, Timmers MC, Veen H van der, Booms P. Sont JK, Sterk PJ. Effect of an inhaled neutral endopeptidase inhibitor, thiorphan, on airway responsiveness to leukotriene D4 in normal and asthmatic subjects. Eur Respir J 1994;7:459-66.
11. Sampson AP, Thomas RU, Costello JF, Piper PJ. Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects. Br J Clin Pharmacol 1992;33:423-30.
12. Weersink EJM, Postma DS, Aalbers R, Monchy JG de. Early and late asthmatic reaction after allergen challenge. Respir Med 1994; 88:103-14.
13. Christie PE, Tagari P, Ford-Hutchinson AW, Black C, Markendorf A. Schmitz-Schumann M, et al. Urinary leukotriene E4 after lysineaspirin inhalation in asthmatic subjects. Am Rev Respir Dis 1992: 146 1531-4.
14. Adelroth E, Morris MM, Hargreave FE, O'Byrne PM. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986; 315:480-4.
15. Bel EH, Veen H van der, Kramps JA, Dijkman JH. Sterk PJ. Maximal airway narrowing to inhaled leukotriene D4 in normal subjects. Comparison and interaction with methacholine. Am Rev Respir Dis 1987;136:979-84.
16. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmastic airways. Lancet 1993;341:989-90.
17. Diamant Z. Hiltermann JT, Rensen EL van, Callenbach PM, Veselic-Charvat MA, Veen H van der, et al. The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 1997;155:1247-53.
18. Cohen P, Noveral JP, Bhala A, Nunn SE, Herrick DJ, Grunstein MM. Leukotriene D4 facilitates airway smooth muscle cell proliferation via modulation of the IGF axis. Am J Physiol 1995:269(2 Pt 1):L151-7.
19. Kurosawa M, Yodonawa S, Tsukagoshi H, Miyachi Y. Inhibition by a novel peptide leukotriene receptor antagonist ONO-1078 of airway wall thickening and airway hyperresponsiveness to histamine induced by leukotriene C4 or leukotriene D4 in guinea-pigs. Clin Exp Allergy 1994;24:960-8.
20. Lambert RK, Wiggs BR, Kuwano K, Hogg JC, Pare PD. Functional significance of increased airwav smooth muscle in asthma and COPD J Appl Physiol 1993;74:2771-81.
21. Diamant Z. Experimental interventions in leukotriene- and allergen-induced airway responses in asthma in vivo [proefschrift]. Leiden: Rijksuniversiteit Leiden, 1996
22. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996;98:1-13.
23. Gaddy JN, Margolskee DJ, Bush RK, Williams VC, Busse WW. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992;146:358-63.
24. Lammers JW, Daele P van, Elshout FMJ van den, Decramer M, Buntinx A, Lepeleire I de. et al Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukast - MK-0679) in asthmatic patients. Pulm Pharmacol 1992,5:121-5.
25. Calhoun WJ, Williams KL, Simonson SG, Lavins BJ. Effect of zafirlukast (Accolate) on airway inflammation after segmental allergen challenge in patients with mild asthma [abstract]. Am J Respir Crit Care Med 1997;155:A662.
26. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cystemyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
27. Makker HK, Lau LC, Thomson HW, Binks SM, Holgate ST. The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147(6 Pt 1):1413-8.
28. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 1992;145(4 Pt 1):746-9.
29. Rasmussen JB, Eriksson LO, Margolskee DJ, Tagari P, Williams VC, Andersson KE. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992;90:193-201.
30. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist N Engl J Med 1990;323:1736-9.
31. Diamant Z, Timmers MC, Veen H van der, Smet M de, Leff JA, Friedman BS, et al. Effect of oral montelukast (MK-0476), a potent leukotriene receptor antagonist, on allergen-induced airway responses in asthmatic subjects [abstract]. Am J Respir Crit Care Med 1996;153:A346.
32. Reiss TF, Bronsky E, Hendeles L, Hill J, Harman E, Guerreiro D, et al. MK-0476, a potent leukotriene (LT)D4 receptor antagonist, inhibits exercise induced bronchoconstriction in asthmatics at the end of a once daily dosing interval [abstract]. Am J Respir Crit Care Med 1995;151:A377.
33. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist. SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991;144:957-8.
34. Dahlen B, Kumlin M, Margolskee DJ, Larsson C. Blomqvist H, Williams VC, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993;6:1018-26.
35. Yamamoto H, Nagata M, Kuramitsu K, Tabe K, Kiucht H, Sakamoto Y, et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994;150:254-7.
36. Suguro H, Majima T, Ichimura K, Hashimoto N, Koyama S, Horie T. Effect of a leukotriene antagonist, Pranlukast hydrate, on exercise-induced bronchoconstriction [abstract]. Am J Respir Crit Care Med 1997;155:A662.
37. Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990;323:1740-4.
38. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Cnt Care Med 1996;153:931-5.
39. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148(6 Pt 1):1447-51.
40. Kane GC, Pollice M, Kim CJ, Cohn J, Dworski RT, Murray JJ, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996;97: 646-54
41. Nasser SM, Bell GS, Foster S, Spruce KE, MacMillan R, Williams AJ, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirininduced asthma. Thorax 1994;49:749-56.
42. Friedman BS, Bel EH, Buntinx A, Tanaka W, Han YH, Shingo S. et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993;147:839-44.
43. Diamant Z, Timmers MC, Veen H van der, Friedman BS, Smet M de, Depre M, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995;95(1 Pt 1):42-51.
44. Hamilton AL, Watson RM, Wyile G, O'Byrne PM. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 1997;52:348-54.
45. Margolskee D, Bodman S, Dockhorn R, Israel E, Kemp J, Mansmann H, et al. The therapeutic effects of MK-571, a potent and selective leuktotriene (LT)D4 receptor antagonist, in patients with chronic asthma [abstract]. J Allergy Clin Immunol 1991,87:309.
46. Suzuki N, Kudo K, Sana Y, Adachi M, Kanazawa M, Kudo S, et al. Efficacy of oral pranlukast, a leukotriene receptor antagonist, in the treatment of asthma: an open study in Tokyo [abstract]. Am J Respir Crit Care Med 1997;155:A664
47. Sahn S, Galant S, Murray J, Bronsky E, Spector S, Faiferman I, et al. Pranlukast (Ultair) improves FEV1 in patients with asthma: results of a 12-week multicenter study vs nedocromil [abstractj. Am J Respir Crit Care Med 1997;155:A665.
48. Tamaoki J, Kondo M, Tagaya E, Takemura H, Nagai A, Takizawa T, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid [abstract]. Am J Respir Crit Care Med 1997;155:A663.
49. Spector SL, Smith LJ, Flass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
50. Micheletto C, Turco P, Dal Negro R. Accolate 20 mg works as steroid sparing in moderate asthma [abstract]. Am J Respir Crit Care Med 1997;155:A664.
51. Reiss TF, Altman LC, Chervinsky P, Bewta A, Stricker WE, Noonan GP, et al Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-34.
52. Reiss TF, Chervinsky P, Edwards T, Dockhorn R, Nayak A, Hess J, et al. Montelukast (MK-0476), a CysLT1 receptor antagonist, improves asthma outcomes over a 3-month treatment period [abstract]. Am J Respir Crit Care Med 1997;155:A662.
53. Leff JA, Israel E, Noonan MJ, Finn AF, Godard P, Lofdahl CG. et al. Montelukast (MK-476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability [abstract]. Am J Respir Crit Care Med 1997;155:A976.
54. Leff JA, Pizzichini E, Efthimiadis A, Boulet LP, Wei LX, Weinland DE, et al. Effect of montelukast (MK-0470) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomized placebocontrolled trial [abstract]. Am J Respir Crit Care Med 1997;155: A977.
55. Fischer AR, McFadden CA, Frantz R, Awni WM, Cohn J. Drazen JM, et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med 1995;152(4 Pt 1):1203-7.
56. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group JAMA 1996;275:931-6.
57. LIU MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial Zileuton Study Group. J Allergy Clin Immunol 1996;98(5 Pt 1):859-71.
58. Fujimura M. Sakamoto S, Kamio Y, Matsuda T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med 1993;87:133-8.
59. McGill KA, Busse WW, Zileuton. Lancet 1996;348:519-24
60. Israel E, Cohn J. Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with athma A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996;275:931-6.
61. Robuschi M, Riva E, Fuccella LM, Vida E, Barnabe R, Rossi M, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis 1992; 145:1285-8.
62. Hofstra WB, Sterk PJ, Neijens HJ, Weij AM van der, Zoest JGCM van, Duiverman EJ. Two weeks treatment with zafirlukast (AccolateTM), sodium cromoglycate or placebo on exercise-induced bronchoconstriction in asthmatic adolescents. Am J Respir Crit Care Med 1997;155:A665.
63. Knorr BA, Matz J, Bernstein JA, Becker A, Reiss T, Friedman B, et al. Montelukast (MK-0476) improves asthma over a 2 month treatment period in 6- to 14-year olds. Am J Respir Crit Care Med 1997;155:A664.